Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206726 | 0.86 | CYP1A1 (0.35) | CYP1A1CYP1B1TYMS | |
| SCHEMBL5949367 | 0.79 | IMPDH2 (0.55) | IMPDH2IMPDH1 | |
| SCHEMBL208076 | 0.76 | LOXL2 (0.37) | TYMS | |
| SCHEMBL208273 | 0.72 | LOXL2 (0.40) | TYMS | |
| SCHEMBL29870412 | 0.71 | CYP1A1 (0.54) | CYP1A1CYP1B1TYMS | |
| SCHEMBL1478481 | 0.71 | CYP1A1 (0.54) | CYP1A1CYP1B1TYMS | |
| SCHEMBL1022937 | 0.71 | IMPDH2 (0.66) | IMPDH2IMPDH1 | |
| SCHEMBL10481157 | 0.69 | CYP1A1 (0.52) | CYP1A1CYP1B1TYMS | |
| SCHEMBL12986899 | 0.69 | CYP1A1 (0.52) | CYP1A1CYP1B1TYMS | |
| SCHEMBL29832259 | 0.69 | CYP1A1 (0.52) | CYP1A1CYP1B1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | claimed |
| EP-1270557-B1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-07-25 | — | — | EP | claimed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | claimed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | claimed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | claimed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | claimed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | claimed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | claimed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | claimed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | claimed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | claimed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | claimed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | claimed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | claimed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | CYP1A1 1867/4885CYP1B1 2830/4885IMPDH2 4666/4885 |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | CYP1A1 110/4885CYP1B1 167/4885IMPDH2 4646/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | CYP1A1 1841/4885CYP1B1 3156/4885IMPDH2 4151/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | CYP1A1 1123/4885CYP1B1 1887/4885IMPDH2 3478/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | CYP1A1 1123/4885CYP1B1 1887/4885IMPDH2 3478/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | CYP1A1 1123/4885CYP1B1 1887/4885IMPDH2 3478/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | CYP1A1 105/4885CYP1B1 143/4885IMPDH2 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.